Lipocine’s LPCN 1154 Shows Mixed Results in Treating Postpartum Depression During Phase 3 Trial Lipocine Inc.'s Phase 3 trial results for LPCN 1154 in postpartum depression reveal mixed efficacy and a well-tolerated safety profile among participants.

Lipocine’s LPCN 1154 Shows Mixed Results in Treating Postpartum Depression During Phase 3 Trial #USA #Salt_Lake_City #Lipocine #LPCN_1154 #postpartum_depression

Lipocine's 2025 Financial Report Highlights Pipeline Progress and Market Opportunities Lipocine Inc. shared its financial results for 2025, showcasing significant pipeline developments for mental health and metabolic disorders, setting the stage for future progress.

Lipocine's 2025 Financial Report Highlights Pipeline Progress and Market Opportunities #United_States #Salt_Lake_City #Lipocine #LPCN_1154 #TLANDO

Lipocine's LPCN 1154 Marks Final Phase 3 Trial Visit for PPD Treatment Lipocine Inc. completes the last patient visit in the Phase 3 trial of LPCN 1154, an oral treatment for postpartum depression (PPD), showing positive safety results.

Lipocine's LPCN 1154 Marks Final Phase 3 Trial Visit for PPD Treatment #USA #Salt_Lake_City #Lipocine #LPCN_1154 #postpartum_depression

Lipocine Completes Phase 3 Trial Enrollment for LPCN 1154 Targeting Postpartum Depression Lipocine has finished participant enrollment and dosing in its Phase 3 clinical trial for LPCN 1154, aimed at treating postpartum depression. Initial results are promising.

Lipocine Completes Phase 3 Trial Enrollment for LPCN 1154 Targeting Postpartum Depression #United_States #Salt_Lake_City #Lipocine #LPCN_1154 #postpartum_depression

Lipocine's LPCN 1154 Shows Positive Results in PPD Phase 3 Trial Review Lipocine Inc. announced the successful completion of an independent safety review for LPCN 1154 in a Phase 3 trial targeting postpartum depression, reinforcing confidence in its efficacy.

Lipocine's LPCN 1154 Shows Positive Results in PPD Phase 3 Trial Review #USA #Salt_Lake_City #Lipocine #LPCN_1154 #postpartum_depression

Lipocine Reaches Milestone in Phase 3 Study for Postpartum Depression Treatment Lipocine Inc. has achieved 80% enrollment in its Phase 3 clinical trial for LPCN 1154, an innovative treatment for postpartum depression (PPD).

Lipocine Reaches Milestone in Phase 3 Study for Postpartum Depression Treatment #USA #Salt_Lake_City #Lipocine #LPCN_1154 #PPD_Treatment

Lipocine Reports Q3 2025 Financial Results and Clinical Updates Lipocine Inc. announces third quarter financial results for 2025 and updates on clinical trials, including LPCN 1154 for postpartum depression.

Lipocine Reports Q3 2025 Financial Results and Clinical Updates #USA #Salt_Lake_City #Lipocine #LPCN_1154 #TLANDO

Lipocine's LPCN 1154 Phase 3 Trial Progress in Treating Postpartum Depression Lipocine Inc. shares an update on its Phase 3 trial of LPCN 1154 for postpartum depression, with promising enrollment and safety review plans.

Lipocine's LPCN 1154 Phase 3 Trial Progress in Treating Postpartum Depression #United_States #Salt_Lake_City #Lipocine #LPCN_1154 #postpartum_depression

Lipocine Reports Second Quarter Financial Results and Updates on Pivotal Studies Lipocine Inc. shares Q2 financial results and advancements on LPCN 1154, a treatment for postpartum depression, alongside updates on LPCN 2401.

Lipocine Reports Second Quarter Financial Results and Updates on Pivotal Studies #USA #Salt_Lake_City #Lipocine #LPCN_1154 #TLANDO

Lipocine's Virtual Investor Event on LPCN 1154 for Postpartum Depression Set for July 2025 Join Lipocine's virtual R&D investor event on July 9, 2025, to explore LPCN 1154's potential in treating postpartum depression, alongside expert insights.

Lipocine's Virtual Investor Event on LPCN 1154 for Postpartum Depression Set for July 2025 #USA #Salt_Lake_City #Lipocine #LPCN_1154 #postpartum_depression

Lipocine Inc.: Key Financial Update and Future Developments as of Q1 2025 Lipocine Inc. announces its financial performance for Q1 2025, highlighting key developments and ongoing studies towards innovative treatments.

Lipocine Inc.: Key Financial Update and Future Developments as of Q1 2025 #United_States #Salt_Lake_City #LPCN_1154 #TLANDO #Lipocine_Inc

Lipocine Begins Phase 3 Trial for LPCN 1154 to Treat Postpartum Depression Lipocine Inc. has launched a Phase 3 trial for LPCN 1154, aimed at treating postpartum depression through effective oral delivery.

Lipocine Begins Phase 3 Trial for LPCN 1154 to Treat Postpartum Depression #United_States #Salt_Lake_City #Lipocine #LPCN_1154 #postpartum_depression

Lipocine Advances Critical Regulatory Journey for LPCN 1154 in Treating Postpartum Depression Lipocine's latest regulatory guidance suggests further safety and efficacy trials for LPCN 1154, aiming to address postpartum depression in women rapidly.

Lipocine Advances Critical Regulatory Journey for LPCN 1154 in Treating Postpartum Depression #USA #Salt_Lake_City #Lipocine #LPCN_1154 #postpartum_depression